Newsroom

Sorted by: Latest

-

INFORME DE TELETRAC NAVMAN: EL 84 % DE LAS FLOTAS CITAN LA EXONERACIÓN DE LOS CONDUCTORES COMO LA PRINCIPAL RAZÓN PARA IMPLANTAR TECNOLOGÍA DE SEGURIDAD

NORTHBROOK, Illinois--(BUSINESS WIRE)--Una nueva investigación de Teletrac Navman, una plataforma líder en movilidad conectada y empresa de Vontier, ha revelado que el 84 % de las flotas citan la exoneración de los conductores como la razón principal para implementar tecnología de seguridad, además el 53 % de las flotas que sufrieron accidentes en los últimos 12 meses lograron exonerar a un conductor. El informe “Movilizar el futuro de las flotas: edición 2026 sobre riesgos y exoneración” revel...
-

Teletrac Navman Report: 84% of Fleets Cite Driver Exoneration as a Leading Reason for Deploying Safety Technology

NORTHBROOK, Ill.--(BUSINESS WIRE)--New research from Teletrac Navman, a leading connected mobility platform and a Vontier company, has found that 84% of fleets cite driver exoneration as a leading reason for deploying safety technology, with 53% of fleets that suffered accidents in the past 12 months successfully able to exonerate a driver. The ‘Mobilizing the Future of Fleets: 2026 Risk and Exoneration Edition’ uncovered that a third (34%) of fleets reported being impacted by fraudulent motor...
-

QuantumScape Successfully Accomplishes Annual Commercial Engagement Goal

SAN JOSE, Calif.--(BUSINESS WIRE)--QuantumScape Corporation (NYSE: QS), a global leader in next-generation solid-state lithium-metal battery technology, today announced the achievement of its final annual goal for 2025, which targeted a significant expansion in commercial engagement with automotive customers and technology partners. The latest accomplishment in this effort is the signing of a joint development agreement (JDA) with a new automotive OEM customer, a Top-10 global automaker. This a...
-

HSBC Bank Plc UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  15-December-2025 Issue: Co-operative Bank plc CB 2025-1 XS3049417317 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 22-September-2025 Date To: 22-December-2025 Record Date: 19-December-2025 Value Date: 22-December-2025 Benchmark Rate: 3.9885% Margin: 0.57% Total Rate: 4.5585% Floor: 0% Number of Days: 91 Day Count: Actual / 365 (Fixed) Interest Frequency: Quarterly Denominatio...
-

Riassunto: Nexo annuncia un'importante collaborazione con Tennis Australia per l'Australian Open e la Summer of Tennis in materia di criptovalute

LONDRA--(BUSINESS WIRE)--Nexo, importante piattaforma di asset digitali, ha siglato uno storico accordo di collaborazione pluriennale con Tennis Australia ed è diventato Official Crypto Partner degli Australian Open e della Summer of Tennis, che include eventi come la United Cup, l'Adelaide International, il Brisbane International e l'Hobart International. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte...
-

HSBC Bank Plc UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  15-December-2025 Issue: Co-operative Bank plc CB XS2838925902 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 22-September-2025 Date To: 22-December-2025 Record Date: 19-December-2025 Value Date: 22-December-2025 Benchmark Rate: 3.9885% Margin: 0.53% Total Rate: 4.5185% Floor: 0% Number of Days: 91 Day Count: Actual / 365 (Fixed) Interest Frequency: Quarterly Denomination: GBP...
-

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically signific...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 16.12.2025 FEUD IE00BF2FL590  366,243.00 EUR  18,257,327.51   49.850  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 16.12.2025 SDVI.LN IE000YVOQ2A3 40,361.00 USD 1,068,875.16 26.483  ...
-

HSBC Bank Plc UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  15-December-2025 Issue: Clydesdale Bank plc CB Series 10 XS3095269539 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 22-September-2025 Date To: 22-December-2025 Record Date: 19-December-2025 Value Date: 22-December-2025 Benchmark Rate: 3.98849% Margin: 0.8% Total Rate: 4.78849% Floor: 0% Number of Days: 91 Day Count: Actual / 365 (Fixed) Interest Frequency: Quarterly Denominat...